Since METTL3 inactivates CD8+ T cells in NAFLD-HCC microenvironment, this prompted us to explore whether targeting METTL3 could improve ICB therapeutic efficacy for NAFLD-HCC. Here, CD8A is linked to metabolic dysfunction-associated steatotic liver disease.